Repligen Corp Files 8-K on Financials
Ticker: RGEN · Form: 8-K · Filed: Feb 20, 2025 · CIK: 730272
| Field | Detail |
|---|---|
| Company | Repligen Corp (RGEN) |
| Form Type | 8-K |
| Filed Date | Feb 20, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Repligen filed an 8-K detailing financial results and condition.
AI Summary
Repligen Corporation filed an 8-K on February 20, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 41 Seyon Street, Waltham, Massachusetts.
Why It Matters
This filing provides crucial updates on Repligen's financial performance and condition, which is essential for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Repligen Corporation (company) — Registrant
- 41 Seyon Street, Waltham, Massachusetts (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Repligen Corporation's results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K filing submitted?
This 8-K filing was submitted on February 20, 2025.
What is Repligen Corporation's principal executive office address?
Repligen Corporation's principal executive office is located at 41 Seyon Street, Building 1, Suite 100, Waltham, Massachusetts, 02453.
What is Repligen Corporation's fiscal year end?
Repligen Corporation's fiscal year ends on December 31.
What is the SIC code for Repligen Corporation?
The Standard Industrial Classification (SIC) code for Repligen Corporation is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 20, 2025 regarding REPLIGEN CORP (RGEN).